乙酰氧基氨基甲酸叔丁酯 | 99768-83-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 乙酰氧基氨基甲酸叔丁酯
• 英文名称: tert-butyl acetoxycarbamate
• 英文别名: (Acetyloxy)-carbamic acid tert-butyl ester；[(2-methylpropan-2-yl)oxycarbonylamino] acetate
• CAS: 99768-83-9
• 化学式: C₇H₁₃NO₄
• 分子量: 175.185
• InChiKey: JZRZCXCWUWTKQF-UHFFFAOYSA-N

物化性质

• 沸点：
  90 °C(Press: 2.8 Torr)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  乙酰氧基氨基甲酸叔丁酯 在 三氯异氰尿酸 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl N-chloro-N-acetyloxy-carbamate
  参考文献：
  名称：

  Optimization of HNO Production from N,O-bis-Acylated Hydroxylamine Derivatives

  摘要：

  A wide range of N,O-bis-acylated hydroxylamine derivatives with chloro or arenesulfonyl leaving groups, and a related set of N-hydroxy-N-acylsulfonamides, have been synthesized and evaluated for nitroxyl (HNO) production. Mechanistic studies have revealed that the observed aqueous chemistry is more complicated than originally anticipated, and have been used to develop a new series of efficient HNO precursors (4u-4x, 7c-7d) with tunable half-lives.

  DOI：

  10.1021/ol203016c
• 作为产物：
  描述：

  N-重氮基氨基甲酸叔-丁基酯 在 乙醚 、 盐酸羟胺 、 水 、 三乙胺 作用下， 生成 乙酰氧基氨基甲酸叔丁酯
  参考文献：
  名称：

  O-Acylhydroxylamines. I. Synthesis of O-Benzoylhydroxylamine¹

  摘要：

  DOI：

  10.1021/ja01513a049

文献信息

• Certain benzopyran and benzothiopyran derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05155130A1

  公开（公告）日：1992-10-13

  The invention relates to the compounds of the formula ##STR1## wherein each R independently represents hydrogen, lower alkyl, halogen, trifluoromethyl, lower alkoxy, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryloxy, carbocyclic or heterocyclic aryl-lower alkyloxy, carbocyclic or heterocyclic aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyloxy, or C.sub.3 -C.sub.7 -cycloalkyloxy; R.sub.1 represents hydrogen, lower alkyl or carbocyclic aryl; R.sub.2 represents hydrogen or lower alkyl; Y represents oxygen (O), sulfur (S), sulfinyl or sulfonyl; n represents 1, 2 or 3; A represents a direct bond or lower alkylene; Z represents ##STR2## wherein R.sub.3 represents hydrogen or acyl; R.sub.4 represents lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, or C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl; or Z represents ##STR3## wherein X represents oxygen or sulfur, R.sub.3 represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono- or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocyclic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylamino-carbonyl; C.sub.3 -C.sub.7 -cycloalkylaminocarbonyl, or C.sub.3 -C.sub.7 -cycloalkyl-lower alkylaminocarbonyl; R.sub.5 represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C.sub.3 -C.sub.7 -cycloalkylamino, C.sub.3 -C.sub.7 -cycloalkyl-lower alkylamino, lower alkoxycarbonyl-lower alkylamino, or lower alkoxy; R.sub.6 and R.sub.7 independently represent hydrogen or lower alkyl; and pharmaceutically acceptable salts thereof; which are useful as 5-lipoxygenase inhibitors.

  该发明涉及以下式的化合物##STR1##其中每个R独立地代表氢、较低的烷基、卤素、三氟甲基、较低的烷氧基、碳环或杂环芳基、碳环或杂环芳氧基、碳环或杂环芳基-较低烷氧基、碳环或杂环芳基-较低烷基、C.sub.3-C.sub.7-环烷基-较低烷氧基、或C.sub.3-C.sub.7-环烷氧基；R.sub.1代表氢、较低烷基或碳环芳基；R.sub.2代表氢或较低烷基；Y代表氧（O）、硫（S）、亚砜或磺酰基；n代表1、2或3；A代表直链键或较低烷基；Z代表##STR2##其中R.sub.3代表氢或酰基；R.sub.4代表较低烷基、C.sub.3-C.sub.7-环烷基、碳环或杂环芳基、碳环或杂环芳基-较低烷基、或C.sub.3-C.sub.7-环烷基-较低烷基；或Z代表##STR3##其中X代表氧或硫，R.sub.3代表氢、酰基、较低烷氧羰基、氨基羰基、单-或双-较低烷基氨基羰基、较低烯基氨基羰基、较低炔基氨基羰基、碳环或杂环芳基-较低烷基氨基羰基、碳环或杂环芳胺基羰基；C.sub.3-C.sub.7-环烷基氨基羰基，或C.sub.3-C.sub.7-环烷基-较低烷基氨基羰基；R.sub.5代表较低烷基、较低烷氧羰基-较低烷基、C.sub.3-C.sub.7-环烷基、碳环或杂环芳基、碳环或杂环芳基-较低烷基、C.sub.3-C.sub.7-环烷基-较低烷基、氨基、单-或双-较低烷基氨基、较低烯基氨基、较低炔基氨基、碳环或杂环芳基-较低烷基氨基、碳环或杂环芳胺基、C.sub.3-C.sub.7-环烷基氨基、C.sub.3-C.sub.7-环烷基-较低烷基氨基、较低烷氧羰基-较低烷基氨基，或较低烷氧基；R.sub.6和R.sub.7独立地代表氢或较低烷基；及其药学上可接受的盐；这些化合物可用作5-脂氧酶抑制剂。
• NEPRILYSIN INHIBITORS
  申请人：Fleury Melissa

  公开号：US20150210690A1

  公开（公告）日：2015-07-30

  In one aspect, the invention relates to compounds having the formula I: where R 1 -R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一个方面，该发明涉及具有以下式I的化合物： 其中R1-R6如规范中定义，或其药学上可接受的盐。这些化合物具有神经肽酶抑制活性。在另一个方面，该发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Bis-Acylated Hydroxylamine Derivatives
  申请人：Toscano John P.

  公开号：US20110136827A1

  公开（公告）日：2011-06-09

  The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

  这项发明提供了某些双酰化羟胺衍生物化合物，包括这些化合物的药物组合物和试剂盒，以及使用这些化合物或药物组合物的方法。具体而言，该发明提供了使用这些化合物或药物组合物治疗、预防或延缓疾病或病况发生和/或发展的方法。在某些实施例中，疾病或病况可选自心血管疾病、缺血、再灌注损伤、癌症疾病、肺动脉高压和对亚硝酰治疗有反应的病况。
• [EN] PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS À BASE D'ACIDE GAMMA-HYDROXYBUTYRIQUE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：XW LAB INC

  公开号：WO2017049470A1

  公开（公告）日：2017-03-30

  The present application discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

  本申请公开了γ-羟基丁酸的前药，以及其组合物和用途。
• [EN] DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS DIHYDROPYRIMIDINE ET UTILISATIONS DE CEUX-CI EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2019076310A1

  公开（公告）日：2019-04-25

  Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

  本文提供了一种二氢嘧啶化合物及其作为药物的用途，特别是作为用于治疗和预防乙型肝炎的药物的应用。具体而言，本文提供了具有化学式（I）或（Ia）的化合物，或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药学上可接受的盐或其前药，其中化学式的变量如规范中所定义。本文还提供了使用具有化学式（I）或（Ia）的化合物，或其对映体、二对映异构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐作为药物的用途，特别是用作治疗和预防乙型肝炎的药物。